← 返回

追寻治愈:免疫性血小板减少症的现代医学方法

英文原题:The hunt for a cure: modern medical approaches for immune thrombocytopenia.

查看英文原题

The hunt for a cure: modern medical approaches for immune thrombocytopenia.

PubMed 2026/05/26(内容时间) Expert Rev Hematol Q2 · IF 2.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

尽管现代疗法可实现 SROT 和深度免疫破坏,但这是否能转化为对 ITP 病程的实质性改变仍不清楚。

中文摘要

引言:脾切除和干细胞移植过去曾使部分免疫性血小板减少症(ITP)患者获得长期缓解,似乎达到治愈。数十种安全性更好的现代药物治疗已革新 ITP 管理,其中多种可诱导停药后持续缓解(SROT)并推迟复发,为改变疾病进程和治愈带来希望。 综述范围:本文讨论如何定义 ITP 治愈,回顾与疾病修饰相关的关键病理生理机制,介绍历史治疗方式并探讨有希望的现代疗法。根据作者专业经验选取文献。本综述聚焦潜在治愈策略,重点包括揭示免疫复杂性决定因素、自身免疫记忆持续性和治疗耐药/难治性的病理生理研究,以及报告长期缓解和复发率的临床研究;优先纳入临床试验和大型回顾性研究。 专家观点:现代疗法能够实现停药后持续缓解和深度免疫扰动,但这些变化是否会对 ITP 病程产生有意义的改变,目前仍不清楚。随着领域追求治愈,确定预测性生物标志物、开展长期随访临床试验、深入理解自身免疫记忆的病理生理基础,并平衡以患者为中心的风险和毒性考量,均至关重要。

展开英文摘要原文

INTRODUCTION: Splenectomy and stem cell transplant have historically provided long-term remissions that seemingly cure a subset of patients with immune thrombocytopenia (ITP). Dozens of modern medical therapies with better safety profiles have revolutionized ITP treatment and several can induce sustained response off treatment (SROT) and delay relapse, providing hope for disease modification and cure. AREAS COVERED: In this review, we consider how ITP cure might be defined, review key pathophysiologic mechanisms relevant for disease modification, discuss historical approaches, and explore modern therapies that hold promise. Articles were identified based on the authors' expertise.

This review on potential ITP cure focuses on pathophysiologic studies that shed light on determinants of immunologic complexity, persistence of autoimmune memory, and treatment resistance or refractoriness and clinical studies that report on long-term remission and relapse rates, prioritizing clinical trials and large retrospective studies, where available.

EXPERT OPINION: While SROT and deep immunologic disruption are possible with modern therapies, it remains unknown whether this translates to a meaningful alteration of ITP trajectory. As the field strives for cure, identifying predictive biomarkers, clinical trials incorporating longer follow-up, better understanding of the pathophysiologic underpinnings of autoimmune memory, and balancing patient-focused considerations of risk and toxicity are critical.

论文信息

作者
Jiang D、Kuter DJ
单位
Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.United States
文献类型
综述
期刊
Expert review of hematology2026 Jul
原文标识
PubMed 42161854 · DOI 10.1080/17474086.2026.2678348